Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesAlcohol or Drug Use or Induced Organic Mental DisordersDRG 896-alcohol-drug-abuse-or-dependence-without-rehabilitation-therapy-with-mcc
    Ask Trek AI about this page

    Alcohol, Drug Abuse or Dependence without Rehabilitation Therapy with MCC: Inpatient Reimbursement Overview

    DRG 896 addresses inpatient stays for alcohol, drug abuse, or dependence without rehabilitation therapy when a Major Complication or Comorbidity is present. This Diagnosis-Related Group is clinically focused on substance-related disorders with significant comorbidity and matters for inpatient reimbursement because the increased severity affects Medicare payment classification.

    Customize your policy alerts

    Sign up for drg 896 policy alerts

    Get alerted when payer policies referencing 896 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 896 Overview

    DRG 896 covers hospital admissions for alcohol, drug abuse, or dependence where rehabilitation therapy is not provided and a Major Complication or Comorbidity is present. This Diagnosis-Related Group includes cases with significant medical or psychiatric comorbid conditions that increase resource use during inpatient stays. It matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates the relative weight and reimbursement compared with similar cases without such severity. Accurate clinical documentation of the primary substance-related diagnosis and the Major Complication or Comorbidity is essential for assignment to this Diagnosis-Related Group.

    Table of contents

    Progress1 / 5

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    National Payment Rates

    Across payers, negotiated rates for DRG 896 range from a low near $370 up to $45K, with payer medians spanning roughly $2.1K (BCBS) to $27K (Aetna). The widest spread is seen between BCBS’s lower median and Aetna’s much higher median, indicating significant payer variation; see the table and chart below for payer-specific percentiles and distributions. These differences highlight variation across commercial payers including Blue Cross Blue Shield, Anthem, Cigna, and Aetna.

    The CMS 2023 data are national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 896. These figures reflect Medicare FFS payment activity at the national level for 2023.

    Average Total PaymentAverage Submitted ChargesAverage Medicare PaymentTotal Discharges
    $17K$75K$14K9.2K

    Patient Population

    This DRG’s population includes both Medicare-age beneficiaries and working-age commercially insured patients, representing a mixed-age cohort. Medicare beneficiaries drive a meaningful portion of inpatient utilization given the program’s coverage of older adults, while private/commercial payers cover many younger, working-age patients. Overall, the mix is neither exclusively Medicare-age nor exclusively working-age but spans both groups.

    State Payment Rates

    State: Alaska1 / 49

    Alaska Benchmarks

    Payer means for DRG 896 in Alaska span from $12K (Blue Cross Blue Shield) up to $31K (Cigna), indicating a wide rate range across payers. Cigna’s mean notably exceeds common national central tendencies, producing the largest deviation from national averages. The table and chart below provide the detailed payer distribution and percentiles.

    Key Insights for Alaska

    • Highest-paying payer: Cigna (mean $31K); Lowest-paying payer: BCBS (mean $12K).
    • Alaska’s payer means range from $12K to $31K, a notably higher ceiling than typical national medians where many payers report means below $20K.
    • Anthem’s mean ($17K) sits near the state median, while Cigna’s mean substantially exceeds both state and national central tendencies.

    Clinical Trials

    • Acute inpatient medically supervised withdrawal (detoxification) trials: studies testing protocols for managing severe withdrawal symptoms in hospitalized patients with alcohol or drug dependence who present with life-threatening or complicated withdrawal (presence of comorbid medical illness, high-risk physiology, or co-occurring substance-related medical complications). These trials compare different medication regimens, symptom-monitoring strategies, or care pathways to reduce complications, length of stay, and need for ICU-level care; they focus on the acute stabilization window that defines much of the resource use in this DRG. Results matter to providers and payers because optimizing acute management can decrease morbidity, shorten hospital stays, and reduce high-cost downstream utilization.
    • Comparative effectiveness studies of integrated inpatient medical-psychiatric management versus standard medical care: pragmatic trials enrolling patients with alcohol or drug dependence complicated by major comorbidities (severe liver disease, infections, overdose-related injury, or severe psychiatric comorbidity) to evaluate coordinated models that combine addiction medicine consultation, psychiatric stabilization, and medical treatment during the same admission. These studies examine outcomes such as hospital readmission, 30-day mortality, initiation of evidence-based addiction treatments prior to discharge, and total episode-of-care costs; they address whether early integration changes short-term clinical trajectories and reduces costly recurrent admissions. For providers and payers, evidence in this area guides investment in multidisciplinary teams and billing/resource allocation for high-acuity patients captured by this DRG.
    • Post-discharge linkage and outcomes studies focused on transitions of care and relapse prevention: longitudinal cohort studies or randomized implementation trials that enroll patients discharged after hospitalization for alcohol or drug dependence with major complications, testing interventions to improve linkage to outpatient addiction treatment, medication-assisted therapy initiation, or social supports (housing, case management) in the 30- to 180-day post-discharge period. These trials measure readmissions, overdose events, engagement with outpatient services, and healthcare costs to determine which discharge strategies most effectively reduce recurrent inpatient utilization. Payers and hospital administrators use this evidence to design discharge planning, community partnerships, and value-based care initiatives targeted at patients in this high-risk DRG.

    Related Codes

    894-ALCOHOL-DRUG-ABUSE-OR-DEPENDENCE-LEFT-AMA

    Alcohol, Drug Abuse or Dependence, Left AMA: Inpatient Reimbursement Overview

    895-ALCOHOL-DRUG-ABUSE-OR-DEPENDENCE-WITH-REHABILITATION-THERAPY

    Alcohol, Drug Abuse or Dependence with Rehabilitation Therapy: Inpatient Reimbursement Overview

    897-ALCOHOL-DRUG-ABUSE-OR-DEPENDENCE-WITHOUT-REHABILITATION-THERAPY-WITHOUT-MCC

    Alcohol, Drug Abuse or Dependence without Rehabilitation Therapy without MCC: Inpatient Reimbursement Overview

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Mean Rates by Payer — National — DRG 896
    Mean Rates by Payer — Alaska — DRG 896